. . . thanks for posting the voodoo stock-price analysis, sc . . . anyone who owns a miserable-performing equity like this one needs a laugh now and then . . .
. . . five employees would have been fine with me if that's what OREX's CEO Narachi thought would be the optimum number . . . as a long-time, key executive at Amgen, he knows firsthand how to build a PROFITABLE business . . . a concept that seems lost on some of you folks . . . we'll see . . .
. . . until the September 11 PDUFA date . . . yup, a week from today, arna will begin facing a potentially superior competitor . . . or maybe not . . .
. . . wrote Spencer Osborne: "Right, wrong or indifferent, it is perceived as more effective than Arena's Belviq and safer than Vivus's Qsymia. In fact, it may have just the right attributes to garner approval in Europe, where Belviq and Qsymia both failed." . . . FDA approval tomorrow would be a good first step . . . we'll see . . .
. . . arna's been stinkin' up this sector for two years and you're worried about OREX? . . . too funny, st . . .
. . . any impact, j2, will likely be driven by Contrave's label -- if it's approved . . . that said, I think arna remains significantly overvalued -- and vulnerable -- due to its meager revenues and $900 million market cap . . .
. . . until the September 11 PDUFA date . . . maybe some real competition would sharpen arna's game . . . then again . . .
. . . from the company's 9/2/14 news release: . . . “U.S. Patent No. 8,815,889 claims methods for treating insulin resistance using a composition including naltrexone and bupropion. The patent expires in 2024. . . . A counterpart application to this patent has issued in Europe and other international jurisdictions. . . . NB32 is currently protected by U.S. patent number 7,375,111 and U.S. patent number 7,462,626, which Orexigen refers to collectively as the Weber/Cowley patents and which are expected to expire in 2025/2024. The Weber/Cowley patents cover the current composition of NB32 and methods of administering it to treat obesity. . . . A European counterpart application to the Weber/Cowley patent has issued in the European Patent Office, or EPO, and provides protection for NB32 in the various EPO countries in which the patent has been registered.” . . .
. . . according to a 24/7 WALLst article today: . . . “Orexigen Therapeutics Inc. (NASDAQ: OREX) was started with an Outperform rating and target price of $10.” . . . Arena Pharmaceuticals Inc. (NASDAQ: ARNA) was started with an uninspiring Underperform rating, and with a target price of $3.50.” . . .
. . . "Don't worry, there are no traders buying this dip." . . . probably right, sc . . . they're waiting for the next leg down . . . .
. . . according to a 24/7 WALLst article this week (September 3): . . . “Orexigen Therapeutics Inc. (NASDAQ: OREX) was started with an Outperform rating and target price of $10”. . . . “Arena Pharmaceuticals Inc. (NASDAQ: ARNA) was started with an uninspiring Underperform rating, and with a target price of $3.50.” . . . in case you missed it . . .
. . . Credit Suisse probably understands that OREX’s CEO will focus on building a PROFITABLE pharmaceutical BUSINESS focused on obesity and related disorders – not some money-sapping research fantasy where everybody – except outside shareholders -- gets rich . . . moreover, if OREX is as well-managed as I think it is and it’s successful with Contrave/Empatic in the years ahead, they will likely add products, pipeline and IP through acquisition – like most other successful pharmaceutical companies . . .
. . . why so obsessed with the countdown, d1 . . . seems odd . . . does it remind you -- maybe a little -- too painfully -- of arna’s miserable, downward price trajectory? . . . just curious . . .
. . . gc, why the need to criticize my comments? . . . my OREX shares are rising -- my stinkin' arna shares continue to decline . . . it's that simple . . .
. . . until the September 11 PDUFA date . . . . “As of June 30, 2014, Orexigen had $31.1 million in cash and cash equivalents and an additional $102.2 million in marketable securities, for a total of $133.3 million. Orexigen is eligible to receive cash milestone payments of $100 million from Takeda Pharmaceuticals, between US approval and first commercial sale of NB32.” . . . I thought areniacs said Takeda would drop out of the partnership? . . . when’s that happenin’? . . .
. . . until the September 11 PDUFA date . . . also next month, OREX will submit its responses to the Day 180 List of Outstanding Issues from the EMA's Committee for Medicinal Products for Human Use (CHMP) . . . U.S. and EU approvals for Conrave this year? . . . we’ll see . . .